Right Once for All: Inflammation‐Targeted Zinc–Cobalt Metal–Organic Framework Nanozymes with High Stability and Broad‐Spectrum Synergistic Antibacterial Properties for Accelerating Bacteria‐Infected Wound Healing under Physiological Conditions
Zinc‐modified cobalt‐based metal–organic frameworks (ZCM) can effectively generate abundant reactive oxygen species to heal bacterially infected wounds. However, their instability under physiological conditions not only weakens its catalytic function but also leads to the accumulation of large amoun...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley-VCH
2025-08-01
|
| Series: | Small Structures |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/sstr.202500068 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Zinc‐modified cobalt‐based metal–organic frameworks (ZCM) can effectively generate abundant reactive oxygen species to heal bacterially infected wounds. However, their instability under physiological conditions not only weakens its catalytic function but also leads to the accumulation of large amounts of metal ions, thereby increasing the possibility of new wound infections. In this study, synergistic antibacterial nanoparticles (ZCMCC) are synthesized by loading chlorogenic acid (CGA) on ZCM with chitosan modification to increase the presence of carboxyl groups in the structure and enhance its stability. Meanwhile, ZCMCC exerted broad‐spectrum antibacterial activities against Gram‐negative bacteria (Escherichia coli, 98%), Gram‐positive bacteria (Staphylococcus aureus, 99.4%), and methicillin‐resistant S. aureus (99.3%) by chemodynamic therapy and the release of CGA. Importantly, ZCMCC not only promotes the healing of infected wounds by increasing the expression of the vascular endothelial growth factor α but also targets the infective areas by combining with the CD44. Hence, this research presents a novel approach for creating a synergistic antibacterial system and developing targeted therapies for deep tissue/organ infections in the future. |
|---|---|
| ISSN: | 2688-4062 |